UC Davis Alzheimer's Disease Research Center

加州大学戴维斯分校阿尔茨海默病研究中心

• 批准号: 10666428
• 负责人: Charles DeCarli
• 金额: $ 318.85万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10666428
• 关键词: Acceleration; Address; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease risk; Area; Autopsy; Awareness; Biological Markers; Blood; Caregiver research; Caring; Characteristics; Charge; Clinical; Cognition; Cognitive; Communities; Data; Database Management Systems; Databases; Dementia; Development; Diagnosis; Disease; Disparity; Early Diagnosis; Educational Status; Elderly; Environment; Fostering; Funding; Future; Goals; Health Professional; Heterogeneity; Image; Impaired cognition; Individual; International; Intervention; Investigation; Measures; Mentors; Methods; Mission; Outcome; Participant; Pathologic; Pathology; Persons; Phenotype; Population; Population Heterogeneity; Prevention; Prevention strategy; Qualifying; Research; Research Activity; Research Design; Research Infrastructure; Research Methodology; Research Personnel; Research Support; Resources; Risk Factors; Risk Reduction; Scanning; Science; Secure; Services; Technology; Training and Education; Translational Research; Vascular Diseases; Vision; Walking; aging brain; brain health; career; caregiving; cohort; collaborative environment; dementia risk; design; disparity reduction; education research; effective therapy; epidemiology study; ethnic minority population; ethnoracial; high risk; imaging biomarker; improved; innovation; insight; interdisciplinary collaboration; interest; neuropathology; next generation; novel; prevent; racial minority population; recruit; risk mitigation; stem; therapy development; tool; training opportunity

PROJECT SUMMARY/ABSTRACT - Overall The mission of the UC Davis Alzheimer’s Disease Research Center (UCD ADRC) is to promote a highly innovative and enriched research environment focused on understanding the heterogeneity of brain aging among diverse populations that will ultimately lead to effective therapies to prevent or mitigate dementia. This approach stems from the premise that emphasizing diversity enhances discovery and contributes to translational science as well as reducing disparities in brain health and care. To accomplish this mission, the UCD ADRC has developed innovative methods and a unique study design to recruit and retain a highly demographically diverse clinical and autopsy cohort. All UCD ADRC participants are longitudinally followed and deeply phenotyped with extensive clinical, blood and imaging biomarker measures as well as developing state-of-the-art quantitative neuropathology. The UCD ADRC succeeds at these efforts through a robust research infrastructure, state-of-the-art database management and a highly collaborative environment consisting of seven well integrated resource cores and one research education component (REC) designed to facilitate new research efforts and interventions, dissemination of research findings, education and training as well as encouraging researcher development. Our approach addresses several milestones set by the National Alzheimer’s Project Act to effectively treat Alzheimer’s disease and associated disorders (ADRD) by 2025. These include, but are not limited to: 1) M1.L., evaluating disparities among ethnic and racial minority populations that are at higher risk for AD to mitigate risk and improve cognitive outcomes, 2) M2.H., fully characterizing mixed pathologies and identifying unique risk factors,3) M5-7., accelerating the development of treatments that would prevent, halt, or reverse the course of Alzheimer’s disease (AD), 4) M9., improving early diagnosis through discovery of novel imaging and blood biomarkers, 5) M8., developing novel dementia prevention strategies, and 6) M13.E.,supporting caregiving through funded caregiver research. The UCD ADRC also directly supports multiple epidemiological studies of diverse communities through use of research methods and personnel to gain further insights into dementia risk reduction, early diagnosis, and the impact of various neuropathologies on aging and dementia. Our efforts reflect the evolving needs of an increasingly older and more diverse US population, which is expected to rise to nearly 14 million by midcentury. Moreover, while AD continues to be the major pathological cause of dementia, more recent studies—including one from the UCD ADRC—find that dementia pathology is multifactorial and highly heterogeneous, due in part to the co-occurrence of AD and vascular disease, which varies by ethnoracial characteristics, is emphasized as part of dementia prediction and which can be modified by treatment even in later life. The UCD ADRC is uniquely qualified to support this research focus with a considerable impact on future ADRD diagnosis and treatment.

项目摘要/摘要 - 总体 加州大学戴维斯分校阿尔茨海默氏病研究中心（UCD ADRC）的任务是促进高度 创新且丰富的研究环境专注于了解大脑衰老的异质性 在潜水员中，最终将导致预防或减轻痴呆症的有效疗法。 这种方法从强调多样性的前提下一步 转化科学以及减少大脑健康和护理方面的差异。实现这一目标 任务，UCD ADRC开发了创新的方法和独特的研究设计，以招募和保留 人口统计多样化的临床和尸检队列。所有UCD ADRC参与者都是纵向 紧随其后并深入表型，并通过广泛的临床，血液和成像生物标志物措施以及 发展最新的定量神经病理学。 UCD ADRC通过 强大的研究基础架构，最先进的数据库管理和高度协作的环境 由七个综合资源核心和一个旨在的研究教育部分（REC）组成 促进新的研究工作和干预措施，研究结果的传播，教育和培训 以及鼓励研究人员的发展。我们的方法解决了国家设定的几个里程碑 到2025年，阿尔茨海默氏症的项目法案有效治疗阿尔茨海默氏病和相关疾病（ADRD）。 其中包括但不限于：1）M1.L.评估种族和种族少数群体之间的差异 降低风险和改善认知结果的AD风险较高的人群，2）M2.H.，完全 表征混合病理并确定独特的风险因素，3）M5-7。 可以防止，停止或扭转阿尔茨海默氏病（AD）的治疗方法，4）M9。 通过发现新型成像和血液生物标志物的诊断，5）M8。 预防策略和6）M13.e，通过资助的护理人员研究支持护理。 UCD ADRC还通过研究直接支持潜水员社区的多种流行病学研究 方法和人员可以进一步了解降低痴呆症风险，早期诊断和影响 各种关于衰老和痴呆症的神经病理学。 我们的努力反映了一个越来越老，美国人口越来越多的需求，这就是 预计到本世纪中叶将升至近1400万。而且，尽管广告仍然是主要病理 痴呆症原因，最近的研究 - 包括UCD ADRC的一项研究，并提出痴呆病理学是 多因素且高度异质，部分是由于AD和血管疾病的共同发生 通过民族种族特征的多样性，被强调为痴呆预测的一部分，并且可以修改 即使在以后的生活中进行治疗。 UCD ADRC具有独特的资格来支持这项研究重点 对未来的ADRD诊断和治疗的影响很大。

项目成果

Cholesterol, Amyloid Beta, Fructose, and LPS Influence ROS and ATP Concentrations and the Phagocytic Capacity of HMC3 Human Microglia Cell Line.

• DOI: 10.3390/ijms241210396
• 发表时间: 2023-06-20
• 期刊: International journal of molecular sciences
• 影响因子: 5.6

Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET.

使用全身 EXPLORER PET 对 18F-florbetaben 进行无创定量。

• DOI: 10.21203/rs.3.rs-3764930/v1
• 发表时间: 2023
• 期刊: Research square
• 作者: Holy,EmilyN;Li,Elizabeth;Bhattarai,Anjan;Fletcher,Evan;Alfaro,EvelynR;Harvey,DanielleJ;Spencer,BenjaminA;Cherry,SimonR;DeCarli,CharlesS;Fan,AudreyP
• 通讯作者: Fan,AudreyP

Correction: Association of low-frequency and rare coding variants with information processing speed.

• DOI: 10.1038/s41398-022-01852-x
• 发表时间: 2022-03-01
• 期刊: Translational psychiatry
• 影响因子: 6.8
• 作者: Bressler J;Davies G;Smith AV;Saba Y;Bis JC;Jian X;Hayward C;Yanek L;Smith JA;Mirza SS;Wang R;Adams HHH;Becker D;Boerwinkle E;Campbell A;Cox SR;Eiriksdottir G;Fawns-Ritchie C;Gottesman RF;Grove ML;Guo X;Hofer E;Kardia SLR;Knol MJ;Koini M;Lopez OL;Marioni RE;Nyquist P;Pattie A;Polasek O;Porteous DJ;Rudan I;Satizabal CL;Schmidt H;Schmidt R;Sidney S;Simino J;Smith BH;Turner ST;van der Lee SJ;Ware EB;Whitmer RA;Yaffe K;Yang Q;Zhao W;Gudnason V;Launer LJ;Fitzpatrick AL;Psaty BM;Fornage M;Arfan Ikram M;van Duijn CM;Seshadri S;Mosley TH;Deary IJ
• 通讯作者: Deary IJ

Cardiovascular health and cognitive outcomes: Findings from a biracial population-based study in the United States.

心血管健康和认知结果：美国一项基于混血人口的研究的结果。

• DOI: 10.1002/alz.13421
• 发表时间: 2023
• 期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
• 作者: Dhana,Anisa;DeCarli,CharlesS;Dhana,Klodian;Desai,Pankaja;Holland,ThomasM;Evans,DenisA;Rajan,KumarB
• 通讯作者: Rajan,KumarB

Resources for Enhancing Alzheimer's Caregiver Health in Vietnam (REACH VN): study protocol for a cluster randomized controlled trial to test the efficacy of a family dementia caregiver intervention in Vietnam.

• DOI: 10.1186/s13063-022-06228-6
• 发表时间: 2022-05-09
• 期刊: Trials
• 影响因子: 2.5